Chemosensitization of human glioma cellt to chemotherapeutic agent temozolomide
| Project/Area Number |
20390391
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Fujita Health University |
|---|
Principal Investigator |
HIROSE Yuichi Fujita Health University, 医学部, 教授 (60218849)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SASAKI Hikaru 慶應義塾大学, 医学部, 講師 (70245512)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
UGAWA Fujiko 藤田保健衛生大学, 医学部, 研究補助員 (80465517)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥15,210,000 (Direct Cost: ¥11,700,000、Indirect Cost: ¥3,510,000)
Fiscal Year 2010: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2009: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2008: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
|
|---|
| Keywords | 悪性神経膠腫 / temozolomide / G2チェックポイント / cancer stem cell / グリオーマ / flavopiridol / cyclin-dependent kinase / Aktキナーゼ / DNA二重鎖断裂 / 標的治療 |
|---|
| Research Abstract |
Using human glioma cell line U87MG, biological responses of glioma cells to chemotherapeutic agent temozlomide (TMZ) was investigated. Especially, linkage between G2 checkpoint activation and DNA repair mechanism was thoroughly investigated in order to develop novel TMZ-related therapeutic regime against chemotherapy-refractory gliomas.
|
Report
(4 results)
Research Products
(64 results)
-
-
[Journal Article] Whole genome analysis from microdissected tissue revealed adult supratentorial grade II-III gliomas are divided into clinically relevant subgroups by genetic profile.2011
Author(s)
Hirose Y, Sasaki H, Miwa T, Ohba S, Ikeda E, Abe M, Ikeda S, Kobayashi M, Kawase T, Hasegawa M, Yoshida K.
-
Journal Title
Neurosurgery
Volume: (in press)
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
